Viron Therapeutics wins Prix Galien award for VT-111

Guest Contributor
November 25, 2005

London ON-based Viron Therapeutics Inc has won the prestigious Prix Galien Canada Award for its work developing a class of medicines targeting inflammatory-based disorders. The award was made November 16 and recognizes Viron’s development of VT-111, a class of virally-derived biologics that could revolutionize the way cardiovascular disease is currently treated. VT-111 is currently in Phase II clinical trials for acute coronary syndromes and late preclinical studies for transplant vasculopathy. Viron is a spin off of the Robarts Research Institute and was founded by Dr Grant McFadden, the company’s chief scientific officer and Dr Alexandra Lucas, its chief clinical officer….


Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.